  The COVID-19 pandemic has led to a need for widespread and rapid vaccine
development. As several vaccines have recently been approved for human use or
are in different stages of development, governments across the world are
preparing comprehensive guidelines for vaccine distribution and monitoring. In
this early article, we identify challenges in logistics, health outcomes,
user-centric matters, and communication associated with disease-related,
individual, societal, economic, and privacy consequences. Primary challenges
include difficulty in equitable distribution, vaccine efficacy, duration of
immunity, multi-dose adherence, and privacy-focused record-keeping to be HIPAA
compliant. While many of these challenges have been previously identified and
addressed, some have not been acknowledged from a comprehensive view accounting
for unprecedented interactions between challenges and specific populations. The
logistics of equitable widespread vaccine distribution in disparate populations
and countries of various economic, racial, and cultural constitutions must be
thoroughly examined and accounted for. We also describe unique challenges
regarding the efficacy of vaccines in specialized populations including
children, the elderly, and immunocompromised individuals. Furthermore, we
report the potential for understudied drug-vaccine interactions as well as the
possibility that certain vaccine platforms may increase susceptibility to HIV.
Given these complicated issues, the importance of privacy-focused, user-centric
systems for vaccine education and incentivization along with clear
communication from governments, organizations, and academic institutions is
imperative. These challenges are by no means insurmountable, but require
careful attention to avoid consequences spanning a range of disease-related,
individual, societal, economic, and security domains.
